Page 3 - Brian Markison News Today

11.08.2022 - - Second quarter 2022 UPNEEQ net product sales of $8.4 million; 42% above first quarter - - Opportunity for cash runway to extend through 2023 following recently announced financings - - Expanded Board of Directors with the appointment of Alisa ...

-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend...

-- Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- -- Second quarter 2022 net product... | July 7, 2022

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company,...

12.05.2022 - First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 ...

RVL Pharmaceuticals plc (NASDAQ:NASDAQ:RVLP) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Mitsubishi Logisnext Americas group, a leading North American provider and manufacturer of material handling and innovative automation and...

About Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc (NASDAQ:OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmoticas proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Companys ophthalmic subsidiary supporting ...

Message : Required fields BRIDGEWATER, N.J., May 10, 2021 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company, today announced that its ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakt...